Rontalizumab
Chemical compound
N
Y (what is this?) (verify) Rontalizumab is a humanized monoclonal antibody[1] being developed by Genentech.[2] As of November 2009[update], it is being investigated in a clinical trial for the treatment of systemic lupus erythematosus.[3][4]
References
- ^ WHO Drug Information
- ^ Genentech: Rontalizumab (rhuMAb IFN alpha)
- ^ Clinical trial number NCT00962832 for "A Study to Evaluate the Efficacy and Safety of Rontalizumab in Patients With Moderately to Severely Active Systemic Lupus Erythematosus (ROSE)" at ClinicalTrials.gov
- ^ Misra DP, Negi VS (March 2017). "Interferon targeted therapies in systemic lupus erythematosus". Mediterranean Journal of Rheumatology. 28 (1): 13–19. doi:10.31138/mjr.28.1.13. PMC 7045923. PMID 32185249.
- v
- t
- e
Monoclonal antibodies for the immune system
| Human | |
|---|---|
| Humanized | |
| Veterinary |
| Mouse |
|
|---|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
